LGNDLigand Pharmaceuticals Incorporated

$4B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+32.2% YoY

Gross Profit

$49M96.6% margin

Operating Income

$28M56.2% margin

Net Income

-$7M-13.9% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+51.2%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$29M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$671M

Total Liabilities

$252M

Stockholders' Equity

$419M

Cash & Equivalents

$202M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$38M	+32.2%
Gross Profit	$49M	$35M	+38.1%
Operating Income	$28M	$19M	+46.5%
Net Income	-$7M	-$3M	-124.3%

LGND Q4 2017 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena